Page 7 - 《中国药科大学学报》2025年第5期

学报
Journal of China Pharmaceutical University 2025, 56(5): 539 − 547 539

·药学前沿·

肝脏器官芯片在成药性评价中的应用进展

涂远博 ，徐 晨 ，王译羽 ，王尧龙 ，张峻颖 ，吴春勇 1*
1
1
3
1
2
（ 中国药科大学药学院, 药物分析系, 南京 211198； 昆药集团生物科技（禄丰县）有限责任公司, 楚雄 651212；
1
2
中国药科大学中药学院, 中药制药系, 南京 211198）
3
摘 要 成药性评价是新药研发的核心环节，而现有体外肝脏模型的预测准确性低与成本高昂，是制约该环节的关键瓶颈。
因此，制药行业愈发需要可靠的肝脏体外模型以提高新药研发效率。由于传统动物模型和体外 2D 培养模型在模拟体内生理
和病理上存在着局限性，近年来，借助微流控技术、体外细胞培养技术和生物传感技术的进步，肝脏器官芯片（liver-on-a-chip,
LOC）在新药研发领域日益得到关注，有望成为解决成药性评价痛点的有力武器。本文在介绍肝脏器官芯片构建技术的基
础上，着重从疾病模型构建、药物代谢研究和药物安全性评价等角度总结现有肝脏器官芯片的研究和应用，分析其在成药性
评价中起到的作用，并探讨该领域当前面临的挑战与未来展望。
关键词 肝脏器官芯片；类器官；成药性评价；体外模型；微流控
中图分类号 R318 文献标志码 A 文章编号 1000−5048(2025)05−0539−09
doi：10.11665/j.issn.1000−5048.2024101402

引用本文 涂远博，徐晨，王译羽，等. 肝脏器官芯片在成药性评价中的应用进展 [J]. 中国药科大学学报，2025，56（5）：539 − 547.

Cite this article as: TU Yuanbo, XU Chen, WANG Yiyu, et al. Application of liver-on-a-chip in druggability evaluation[J]. J China Pharm
Univ, 2025, 56(5): 539 − 547.

Application of liver-on-a-chip in druggability evaluation
1
2
1
3
1
TU Yuanbo , XU Chen , WANG Yiyu , WANG Yaolong , ZHANG Junying , WU Chunyong 1*
1 2
Department of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University, Nanjing 211198; Kunming
3
Pharmaceutical Corporation Biotechnology (Lufeng) Co., Ltd., Chuxiong 651212; Department of Traditional Chinese Medicine
Pharmaceutics, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China
Abstract Druggability evaluation is one of the core processes in new drug development, yet the inaccuracy and
high cost of existing in vitro liver models have been a major technical bottleneck, leading to an increasing
demand from the pharmaceutical industry for reliable in vitro liver models to enhance the efficiency of new drug
research and development. Traditional animal models and in vitro 2D culture models have their limitations in
simulating in vivo physiological and pathological conditions, making it challenging to accurately predict drug
efficacy and safety. With the advancement of microfluidic technology, in vitro cell culture, and biosensor
technology, liver-on-a-chip (LOC) has garnered increasing attention in the field of new drug development in
recent years, and is expected to become a powerful tool for addressing the challenges in druggability evaluation.
While introducing the construction technology of LOC, this article mainly summarizes the research and
application of existing LOC from the perspectives of disease model construction, drug metabolism research, and
drug safety evaluation. Furthermore, it analyzes the role of LOC in druggability evaluation and discusses the
current challenges and prospects in this field.
Key words liver-on-a-chip; organoids; druggability evaluation; in-vitro model; microfluidics

This study was supported byYunnan Chunyong Wu Expert Workstation Project (202305AF150034)

收稿日期 2024-10-14 * 通信作者 Tel：025-86185973 E-mail：cywu@cpu.edu.cn
基金项目 云南省吴春勇专家工作站资助项目（202305AF150034）